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Background: With growing concerns about risk of harm from cancer screening, particularly from overdiagnosis, this study aimed
to assess public attitudes to cancer screening in Great Britain.
Methods: We used a population-based survey to assess attitudes to cancer screening, screening history and demographic
characteristics, in men and women aged 50–80 years. Data were collected using face-to-face computer-assisted interviews in 2012.
Results: In our sample of 2024, attitudes to cancer screening were overwhelmingly positive with almost 90% believing that
screening is ‘almost always a good idea’ and 49% saying they would be tested for cancer even if it was untreatable. Attitudes were
particularly positive among those who had previously taken part in breast or colorectal screening.
Conclusions:Our findings suggest that attitudes to cancer screening are very positive in Great Britain. Widespread enthusiasm for
cancer screening may hamper attempts to encourage a greater appreciation of the limitations and potential harms of screening.
Provision of information about cancer screening has been the
subject of much debate in recent years, particularly in relation to
mammography where it has been argued that the risks are
downplayed (Jørgensen and Gøtzsche, 2006; Gøtzsche et al, 2009).
In the United Kingdom, information materials for all three
national cancer screening programmes (breast, cervical and
colorectal) have recently been revised, with the aim of providing
balanced information to allow people to make an informed choice
about participation (Richards, 2011). The underlying model is
‘consider an offer’ (Entwistle et al, 2008), with a clear National
Health Service (NHS) recommendation, but also direct advice to
make an individual decision (Informed Choice about Cancer
Screening, 2014). However, people’s screening decisions are also
likely to be influenced by prevailing public attitudes and, in some
cases, their own past behaviour.
A population survey carried out in the United States in 2001–
2002 found very high levels of enthusiasm for cancer screening
(Schwartz et al, 2004). They speculated that this could be due to
pervasive marketing of screening and a public discourse in which
the limitations of screening are rarely discussed. However, it could
also be a consequence of the intuitive appeal of ‘catching cancer
early’. Although such enthusiasm may promote screening
uptake, it can also lead to dissatisfaction when guidelines are
revised to reduce the recommended frequency or age range for
screening (Squiers et al, 2011; Arkes and Gaissmaier, 2012). It may
also hamper efforts to implement an informed choice approach
because potential participants see no reason to revisit an
‘obvious’ choice.
Cancer screening in Great Britain takes place in a different
context from the United States. Direct-to-consumer marketing is
uncommon, there are few national public health campaigns on
screening, and primary-care physicians have little involvement
in programme delivery (particularly for colorectal screening).
Screening is offered using organised call-recall programmes, in
which routine invitations are sent to all age-eligible adults
alongside information on risks and benefits. The public in Great
Britain has also recently been exposed to media debate about the
risks and benefits of breast screening, including considerable
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publicity surrounding a review of the mammography
programme (Richards, 2011). We assessed enthusiasm for
cancer screening in this context; hypothesising that attitudes in the
Great Britain might be less positive than in the United States
10 years earlier.
METHODS
We commissioned a survey on attitudes to cancer screening in
spring 2012 as part of TNS International’s regular omnibus survey
(TNS International is the name of the research agency we
commissioned to carry out the fieldwork for this study). This is
a weekly, population-based, face-to-face survey, in which clients
can commission questions. Sampling points across England, Scotland
and Wales are selected using random location sampling, stratified by
region and social grade. Local quotas are used to balance the sample
of adults interviewed at eligible addresses and to adjust for likelihood
of being at home. Quotas are set for gender (male/female housewife/
female non-housewife), work status and presence of children. The
survey uses home-based, computer-assisted, personal interviews.
Participants. Adults aged 50–80 years were eligible. All women in
this age-group would have been offered breast screening. Since
1988, women aged 50–70 years have been invited for mammo-
graphy every 3 years, and the programme is currently being
extended to ages 47–49 and 71–73. Both men and women would
have been around the age of eligibility for colorectal screening.
People aged 60–69 years have been offered biennial screening with
faecal occult blood testing since 2006 (with slight variations in
age-ranges between the England, Scotland and Wales), and once-
only flexible sigmoidoscopy screening is currently being imple-
mented at age 55 years (since 2013).
Measures. We included items from the earlier US survey
(Schwartz et al, 2004) to assess enthusiasm for screening (see
Table 1 for item wording). We also asked participants whether they
had ever been screened for breast or colorectal cancer and collected
demographic information.
Analyses. Analyses were carried out using PASW Statistics 18.0
(SPSS Inc., 2009). Weights provided by TNS were applied to the
data in all analyses to adjust the sample to be population-
representative with respect to age, gender, social class and
geographical region. Logistic regression analyses were used to
calculate adjusted odds ratios for endorsement of each screening
attitude by demographic characteristic and screening participation.
RESULTS
Sample characteristics. The overall weighted sample size
was 1895 (51%, n¼ 975 women). Mean age was 63.0 (s.d.¼ 8.6),
most participants were married (60%), and white (94%),
and 39% had no educational qualifications (Appendix 1). Among
those who were age-eligible for screening at the time of the survey,
62% had already had colorectal cancer (CRC) screening (58% of
men and 66% of women) and 86% of women had attended breast
screening.
Overall beliefs. Enthusiasm for screening was extremely high
(Table 1). Nearly 90% of respondents agreed that screening is
‘almost always a good idea’, 75% believed that earlier detection
means treatment can save lives ‘most’ or ‘all’ the time, and 64%
thought early diagnosis means less treatment is needed ‘most’ or
‘all’ the time. Around half (49%) were previously unaware that
some cancers are slow-growing and unlikely to cause problems, but
45% of the total sample wanted to be tested for such a cancer. A
similar proportion (49%) wanted to be tested for a cancer for
which nothing could be done. Almost 60% regarded declining a
screening offer as ‘irresponsible’, and 72% believed they had
received the right number of screening tests in the past.
Demographic variations in beliefs. In adjusted analyses (see
Table 2), the oldest age group were less likely to believe that finding
cancer early means that treatment saves lives (odds ratio
(OR)¼ 0.67, 95% confidence interval (CI): 0.51–0.89) and was
less likely than the younger age group to believe they had
too few screening tests in the past (see Table 2). Men were more
likely than women to want to be tested for an incurable cancer
(OR¼ 1.32, 95% CI: 1.08–1.61) or for a slow-growing cancer
(OR¼ 1.29, 95% CI: 1.06–1.57) and were also more likely to think
they had received too few screening tests in the past (OR¼ 2.82,
95% CI: 2.26–3.54). Men were less likely to have heard of a slow-
growing cancer (OR¼ 0.72, 95% CI: 0.59–0.88). Participants with
no educational qualifications were more likely to think that
screening non-attendance is irresponsible (OR¼ 1.26, 95% CI:
1.02–1.56) but less likely to have heard of a slow-growing cancer
(OR¼ 0.47, 95% CI: 0.38–0.57). Those of non-white ethnicity were
less likely to believe screening is a good idea (OR¼ 0.27, 95% CI:
0.15–0.50) and that screening non-attendance is irresponsible
(OR¼ 0.56, 95% CI: 0.34–0.91). Those who were not married were
less likely to be aware of a slow-growing cancer (OR¼ 0.77, 95%
CI: 0.63–0.94).
Associations between beliefs and previous screening attendance.
After controlling for demographic variables, non-participation in
CRC screening was associated with less positive beliefs about the
benefits of screening, lower awareness of slow-growing cancers, less
enthusiasm for being tested for untreatable or slow-growing
cancers, lower odds of believing that non-attendance is irrespon-
sible and higher odds of believing that one has had too few
screening tests in the past (see Table 2).
Table 1. Enthusiasm for screening
Item Response N (%)
Do you think routine cancer screening tests for Yes 1682 (88.8)
healthy people are almost always a good idea? No 137 (7.3)
Do not know 75 (4.0)
How often does finding cancer early mean that
treatment saves lives?
None 19 (1.0)
Some 462 (24.4)
Most 982 (51.8)
All the time 432 (22.8)
How often does finding cancer early mean that None 50 (2.6)
a person can have less treatment? Some 630 (33.2)
Most 915 (48.3)
All the time 301 (15.9)
Have you ever heard of cancers that grow so Yes 873 (46.1)
slowly that they are unlikely to cause you any No 929 (49.0)
problems in your lifetime? Do not know 92 (4.9)
Would you want to be tested to see if you had a Yes 861 (45.4)
slow-growing cancer like that? No 876 (46.2)
Do not know 158 (8.3)
If there was a kind of cancer for which nothing Yes 931 (49.1)
could be done, would you want to be tested to No 774 (40.8)
see if you had it? Do not know 190 (10.1)
In the past, do you think you have had too many Too few 504 (26.6)
screening tests for cancer, too few or about the About right 1360 (71.8)
right number Too many 31 (1.6)
Do you feel that someone [who] does not go for Yes 1112 (58.7)
screening is irresponsible? No 624 (32.9)
Do not know 159 (8.4)
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A similar pattern of findings was observed for breast
screening, but there was no association between previous
attendance and either awareness of, or desire to be tested for,
a slow-growing cancer. The association with the belief that
finding cancer early means less treatment was also non-
significant.
Table 2. Associations between screening beliefs, demographic factors and screening experience
Routine screening is
a good idea
Finding cancer early means
treatment saves lives
Finding cancer early means
less treatment
Not going for screening
is irresponsible
Yes n (%)
Adjusted OR for
responding ‘yes’
(95% CI)
Most/all of
the time
n (%)
Adjusted OR for
‘most/all the time’
(95% CI)
Most/all of
the time
n (%)
Adjusted OR for
‘most/all the
time’ (95% CI) Yes n (%)
Adjusted OR
for ‘yes’
(95% CI)
Demographic factors
Age
50–59 years 652 (93.0) 1.00 555 (76.7) 1.00 460 (63.5) 1.00 402 (60.5) 1.00
60–69 years 606 (92.9) 0.95 (0.60–1.51) 508 (75.4) 0.84 (0.64–1.10) 438 (65.0) 1.00 (0.79–1.27) 411 (65.7) 1.21 (0.95–1.54)
70–80 years 424 (90.8) 0.68 (0.42–1.08) 351 (70.6) 0.67 (0.51–0.89) 318 (63.9) 0.98 (0.77–1.26) 298 (67.1) 1.21 (0.94–1.56)
Gender
Women 861 (92.0) 1.00 722 (74.1) 1.00 615 (63.1) 1.00 597 (66.5) 1.00
Men 821 (93.0) 1.13 (0.79–1.61) 692 (75.2) 1.10 (0.86–1.37) 600 (65.3) 1.12 (0.92–1.37) 515 (61.5) 0.82 (0.67–1.01)
Qualifications
Any 1021 (92.6) 1.00 847 (74.6) 1.00 728 (64.1) 1.00 651 (61.4) 1.00
None 654 (92.4) 0.99 (0.68–1.46) 556 (75.2) 1.16 (0.92–1.45) 477 (64.5) 1.05 (0.86–1.28) 456 (68.1) 1.26 (1.02–1.56)
Ethnicity
White 1604 (93.2) 1.00 1343 (75.3) 1.00 1157 (64.9) 1.00 1070 (64.9) 1.00
Non-white 72 (80.9) 0.27 (0.15–0.50) 67 (69.1) 0.63 (0.39–1.03) 56 (57.7) 0.71 (0.45–1.12) 38 (48.7) 0.56 (0.34–0.91)
Marital status
Married 1019 (93.0) 1.00 862 (76.1) 1.00 746 (65.9) 1.00 657 (63.1) 1.00
Not married 663 (91.7) 0.80 (0.56–1.14) 552 (72.4) 0.83 (0.66–1.03) 470 (61.6) 0.82 (0.68–1.00) 454 (65.4) 1.01 (0.82–1.24)
Screening experience
Colorectala
Ever screened 522 (95.4) 1.00 448 (79.4) 1.00 392 (69.5) 1.00 383 (72.0) 1.00
Never screened 295 (89.4) 0.39 (0.24–0.66) 229 (66.2) 0.49 (0.36–0.66) 195 (56.5) 0.55 (90.41–0.73) 180 (57.9) 0.50 (0.37–0.68)
Breasta
Ever screened 586 (94.5) 1.00 495 (78.0) 1.00 414 (65.2) 1.00 411 (69.8) 1.00
Never screened 82 (81.3) 0.27 (0.14–0.52) 66 (64.7) 0.52 (0.33–0.82) 57 (55.9) 0.71 (0.46–1.10) 47 (49.0) 0.45 (0.28–0.71)
Want to be tested for
a cancer for which nothing
can be done
Heard of a slow-growing
cancer
Want to be tested for
a slow-growing cancer
Too few screening
tests in the past
Yes n (%)
Adjusted OR
(95% CI) Yes n (%)
Adjusted
OR (95% CI) Yes n (%)
Adjusted OR
(95% CI)
Too few
n (%)
Adjusted OR
(95% CI)
Demographic factors
Age
50–59 years 369 (56.8) 1.00 336 (48.6) 1.00 340 (50.9) 1.00 252 (34.8) 1.00
60–69 years 335 (54.1) 0.89 (0.70–1.14) 332 (51.4) 1.25 (0.99–1.58) 309 (50.2) 0.94 (0.74–1.19) 155 (23.0) 0.53 (0.41–0.69)
70–80 years 227 (52.1) 0.87 (0.68–1.12) 206 (44.1) 1.07 (0.84–1.38) 211 (46.6) 0.83 (0.65–1.06) 97 (19.5) 0.46 (0.35–0.60)
Gender
Women 447 (51.2) 1.00 479 (51.2) 1.00 412 (46.2) 1.00 169 (17.3) 1.00
Men 484 (58.2) 1.32 (1.08–1.61) 394 (45.4) 0.72 (0.59–0.88) 449 (53.1) 1.29 (1.06–1.57) 334 (36.3) 2.82 (2.26–3.54)
Qualifications
Any 588 (56.9) 1.00 609 (55.6) 1.00 522 (49.4) 1.00 330 (29.0) 1.00
None 339 (51.2) 0.84 (0.68–1.03) 261 (37.2) 0.47 (0.38–0.57) 336 (49.9) 1.10 (0.90–1.34) 171 (23.2) 0.91 (0.72–1.14)
Ethnicity
White 887 (55.0) 1.00 835 (48.8) 1.00 816 (49.5) 1.00 463 (26.0) 1.00
Non-White 39 (48.1) 0.68 (0.42–1.11) 36 (43.4) 0.78 (0.48–1.29) 40 (50.0) 0.96 (0.59–1.56) 36 (37.5) 1.26 (0.76–2.08)
Marital status
Married 572 (56.5) 1.00 554 (51.3) 1.00 531 (51.0) 1.00 314 (27.7) 1.00
Not married 358 (51.8) 0.89 (0.73–1.09) 319 (44.1) 0.77 (0.63–0.94) 330 (47.3) 0.90 (0.74–1.10) 190 (24.9) 1.08 (0.86–1.35)
Screening experience
Colorectala
Ever screened 310 (60.2) 1.00 299 (54.7) 1.00 290 (55.9) 1.00 101 (17.9) 1.00
Never screened 140 (44.3) 0.50 (0.37–0.66) 127 (39.4) 0.60 (0.45–0.79) 127 (40.3) 0.50 (0.37–0.67) 98 (28.4) 1.82 (1.30–2.55)
Breasta
Ever screened 315 (54.0) 1.00 325 (52.4) 1.00 290 (49.9) 1.00 103 (16.2) 1.00
Never screened 38 (41.3) 0.59 (0.37–0.93) 53 (55.2) 1.21 (0.78–1.88) 37 (39.4) 0.65 (0.41–1.03) 32 (31.7) 2.09 (1.27–3.45)
All odds ratios are adjusted for age, gender, education, ethnic group and marital status. ‘Do not know’ responses are treated as missing in all analyses. Sample sizes vary due to missing data.
Bold indicates a significant odds ratio (Po0.05)
aAnalyses include only age-eligible participants.
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DISCUSSION
Our findings suggest that enthusiasm for cancer screening in Great
Britain in 2012 is at least as high as in the United States 10 years
earlier (Schwartz et al, 2004). The association between past
screening attendance and enthusiasm was not universal and was, to
some extent, programme-specific. It is striking that enthusiasm was
so high despite screening participation (in this sample and in the
wider UK population) being considerably lower –54% for CRC
screening nationally (von Wagner et al, 2011). This is consistent
with the idea that, although people might ‘know’ that screening is a
good idea, they may hold contradictory beliefs or not get round to
participating.
Men’s greater enthusiasm for being tested for slow-growing and
incurable cancers may be the result of lower exposure to screening
and less familiarity with issues of overdiagnosis. This, together with
their belief that they have had too few screening tests, is consistent
with positive attitudes to prostate specific antigen (PSA) testing in
men (Chapple et al, 2008). This is a key area for future
investigation.
The similarity in attitudes in Great Britain and the United States
raises the possibility that positive appraisal of screening is less due
to marketing and public health campaigns (as Schwartz et al (2004)
suggest), because both are less pervasive in Britain, but arises from
a lay logic that earlier interception of the oncogenic process is
beneficial, perhaps reinforced by public discourse around the value
of prevention and early diagnosis. In addition, the fact that many
respondents in both countries would want to know about an
untreatable cancer suggests that knowledge of health status per se is
valued. Taken together, these results highlight the challenge of
communicating the benefit/harm balance of any particular screen-
ing modality (see for example, Brawley et al, 2011) and suggest that
the public is probably relatively unresponsive to media debate on
overdiagnosis.
The study has a number of limitations, the most important of
which is that TNS International are not able to supply information
on response rate. Although weighting the data goes some way to
adjusting for non-response bias, the generalisability of the findings
is uncertain given the unknown response rate.
Medical concerns about an ‘epidemic’ of overdiagnosis
(Hoffman and Cooper, 2012) will be hard to communicate in the
presence of such enthusiasm. Positive attitudes towards screening
may make participation a reflexive process, inhibiting a ‘rational’
appraisal of risk/benefit information. These findings indicate the
need for further work to explore ways of encouraging active
engagement with screening decisions.
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APPENDIX 1
Appendix 1. Sample characteristics
N (%)
unweighted
N (%) With
weights applieda
All 2024 1895
Gender
Male 951 (47.0) 920 (48.5)
Female 1073 (53.0) 975 (51.5)
Age group
50–59 years 658 (32.5) 724 (38.2)
60–69 years 723 (35.7) 674 (35.6)
70–80 years 643 (31.8) 498 (26.3)
Marital status
Married 1167 (57.7) 1132 (59.8)
Single/separated/widowed/divorced 857 (42.3) 763 (40.2)
Ethnicity
White 1914 (94.6) 1784 (94.1)
Non-white 96 (4.7) 97 (5.1)
Educational qualifications
None 871 (43.0) 738 (39.0)
Any educational qualifications 1132 (57.0) 1136 (60.6)
Colorectal screening history (n¼1028)
Eligible and ever attended 636 (61.9) 564 (62.0)
Eligible and never attended 392 (38.1) 345 (38.0)
Breast screening history (n¼777)
Eligible and ever attended 666 (85.7) 635 (86.2)
Eligible and never attended 111 (14.2) 101 (13.8)
aWeights are used to adjust the sample to be representative of the wider population of
Great Britain with respect to gender, age, social class and geographical region. As weights
may be o1, the overall sample size is reduced when weights are applied.
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